Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Lynparza for Ovarian Cancer

FDA news release; 2017 Aug 17

The FDA has approved Lynparza (olaparib) for the maintenance treatment of patients with ovarian cancer.

Indications: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Dosage and administration: 300 mg taken orally twice daily with or without food.

Efficacy and safety: Approval is based on results of 2 randomized, placebo-controlled, double-blind, multicenter trials which demonstrated statistically significant improvement in progression-free survival in patients receiving Lynparza, vs those treated with placebo.

Side effects/risks: The most common adverse reactions are anemia, nausea, fatigue, vomiting, nasopharyngitis/upper respiratory tract infection/influenza, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitis.

Citation:

FDA approves olaparib tablets for maintenance treatment in ovarian cancer [news release]. Silver Spring, MD: FDA. August 17, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm. Accessed August 27, 2017.

Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf. Accessed August 27, 2017.

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf

Must Reads in FDA Actions

Nivolumab plus ipilimumab approved for advanced RCC, FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm604685.htm

FDA Approves Lynparza for Certain Types of BC, FDA news release; 2018 Jan 12

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Varubi Approved for Delayed Nausea and Vomiting, Tesaro news release; 2017 Oct 25